- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04375735
London's Exogenous Surfactant Study for COVID19 (LESSCOVID)
Phase I/II Trial: Exogenous Surfactant Administration for Patients With COVID-19
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The most severe patients infected by the virus that causes COVID-19 develop severe respiratory failure (called ARDS) and require mechanical ventilation in the intensive care unit to help maintain oxygen delivery to the blood. Often these patients further deteriorate while on mechanical ventilation. This trial will determine the feasibility and safety of a therapy that can potentially improve lung function, reduce the need for mechanical ventilation and hopefully impact mortality.
Adult patients with COVID-19 induced respiratory failure will be randomly assigned to receive either standard treatment or standard treatment plus exogenous surfactant. If enrolled in the latter, exogenous surfactant will be instilled into the lungs within 48 hours of intubation.
The study is founded on extensive research on ARDS for over 30 years, leading to evidence suggesting that exogenous surfactant administration may be beneficial in this disease. Importantly, exogenous surfactant is already utilized all over the world to reduce mortality in preterm infants. When tested in adults with ARDS, it was shown to be well tolerated and safe. Furthermore, clinical and laboratory evidence suggests that this therapy may be most effective in patients with a direct lung infection, and when administered shortly after the patient is intubated. In this study, twenty patients who are proven COVID-19 positive and require MV due to progressive respiratory failure will be randomized to receive either 1) exogenous surfactant (BLES) as soon as possible and within 48 hours of intubation and stabilization, or 2) treatment as usual (will not be treated with surfactant). The overall goal is to improve the outcome (mortality) of mechanically ventilated COVID-19 patients. Although the investigators anticipate that clinical outcomes may improve in the small group of patients receiving exogenous surfactant therapy in this small, single center study, the primary goal is to first determine feasibility and safety. Should the investigators obtain promising results, the data obtained from this study will be used to develop a large trial to test the impact of this therapy on the clinical outcomes, including mortality, associated with COVID-19.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Centre - University Hospital
-
London, Ontario, Canada
- Victoria Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age over 18 years
- definitive proof of COVID-19 infection within 48 hours of intubation
- acute respiratory failure with PaO2/FiO2 < 300 requiring intubation
Exclusion Criteria:
- known or high suspicion of pre-existing heart failure, unstable angina
- presence of severe shock with hemodynamic instability despite escalating vasopressors
- severe, underlying lung disease (COPD, pulmonary fibrosis, lung cancer. etc.)
- Concurrent treatments are delivered directly into the lung (ie anesthetics etc)
- Diagnosis of pulmonary hemorrhage
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BLES treatment
For patients randomized to the treatment arm, exogenous BLES will be administered as soon as possible and within 48 hours of intubation.
BLES will be administered daily for up to 3 doses, or until the patient is liberated from the ventilator.
|
BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered.
The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken.
Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between.
The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses.
To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused.
The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
Other Names:
|
No Intervention: Control
Patients will receive standard treatment and will not receive surfactant.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events (patient) - Decrease in oxygenation
Time Frame: 3 days post-randomization
|
Count of any decreases in oxygenation, expressed as PaO2 (mmHg) / FiO2 (% oxygen as a decimal), of greater than 20% during the BLES treatment and up to 30 minutes post-treatment.
Change will be calculated relative to pre-treatment values.
|
3 days post-randomization
|
Adverse events (patient) - Decrease in hemodynamics
Time Frame: 3 days post-randomization
|
Count of any decrease in mean arterial blood pressure >10 mmHg or requirement for >20% increase in vasopressor dose during the BLES procedure and up to 30 minutes post-treatment.
Change will be calculated relative to the pre-treatment values.
|
3 days post-randomization
|
Adverse event (healthcare worker) - Circuit breach
Time Frame: 3 days post-randomization
|
Number of circuit breaches.
Count of any circuit breach immediately prior to and during each BLES treatment procedure will be recorded.
|
3 days post-randomization
|
Adverse event (healthcare worker) - COVID-19 symptoms
Time Frame: 2 weeks post-randomization
|
Count of healthcare personnel involved in the BLES procedure developing symptoms and testing positive for COVID-19.
|
2 weeks post-randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in oxygenation
Time Frame: Every 12 hours post-randomization until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 days.
|
PaO2 (in mmHg) / FiO2 (percentage oxygen expressed as a decimal) ratios captured from clinical chart
|
Every 12 hours post-randomization until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 days.
|
Change in Lung compliance
Time Frame: Every 12 hours post-randomization until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 days.
|
Lung compliance captured from the ventilators, expressed in mL/cm H2O.
|
Every 12 hours post-randomization until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 days.
|
Ventilated days
Time Frame: From ICU admission until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 days
|
The number of days the patient is receiving mechanical ventilation.
|
From ICU admission until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 days
|
Length of ICU stay
Time Frame: From ICU admission until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 days
|
The number of days the patient is admitted to the ICU
|
From ICU admission until ICU discharge or death, whichever comes first, an average of 10 days and assessed up to 30 days
|
Length of hospital stay
Time Frame: From hospital admission until hospital discharge or death, whichever comes first, assessed up to 60 days
|
The number of days the patient is admitted to the hospital
|
From hospital admission until hospital discharge or death, whichever comes first, assessed up to 60 days
|
Mortality
Time Frame: 30 days
|
Number of patients who die within 30 days of ICU admission
|
30 days
|
G-CSF levels (serum inflammatory biomarker)
Time Frame: ICU day 0, 1, 3 and 7 (7 days)
|
G-CSF, in pg/mL, from multiplex cytokine arrays
|
ICU day 0, 1, 3 and 7 (7 days)
|
GM-CSF levels (serum inflammatory biomarker)
Time Frame: ICU day 0, 1, 3 and 7 (7 days)
|
GM-CSF, in pg/mL, from multiplex cytokine arrays
|
ICU day 0, 1, 3 and 7 (7 days)
|
IFN gamma levels (serum inflammatory biomarker)
Time Frame: ICU day 0, 1, 3 and 7 (7 days)
|
IFN gamma, in pg/mL, from multiplex cytokine arrays
|
ICU day 0, 1, 3 and 7 (7 days)
|
IL-1 beta levels (serum inflammatory biomarker)
Time Frame: ICU day 0, 1, 3 and 7 (7 days)
|
IL-1 beta, in pg/mL, from multiplex cytokine arrays
|
ICU day 0, 1, 3 and 7 (7 days)
|
IL-4 levels (serum inflammatory biomarker)
Time Frame: ICU day 0, 1, 3 and 7 (7 days)
|
IL-4, in pg/mL, from multiplex cytokine arrays
|
ICU day 0, 1, 3 and 7 (7 days)
|
IL-6 levels (serum inflammatory biomarker)
Time Frame: ICU day 0, 1, 3 and 7 (7 days)
|
IL-6, in pg/mL, from multiplex cytokine arrays
|
ICU day 0, 1, 3 and 7 (7 days)
|
IL-10 levels (serum inflammatory biomarker)
Time Frame: ICU day 0, 1, 3 and 7 (7 days)
|
IL-10, in pg/mL, from multiplex cytokine arrays
|
ICU day 0, 1, 3 and 7 (7 days)
|
I levels (serum inflammatory biomarker)
Time Frame: ICU day 0, 1, 3 and 7 (7 days)
|
I, in pg/mL, from multiplex cytokine arrays
|
ICU day 0, 1, 3 and 7 (7 days)
|
MCP-1 levels (serum inflammatory biomarker)
Time Frame: ICU day 0, 1, 3 and 7 (7 days)
|
MCP-1, in pg/mL, from multiplex cytokine arrays
|
ICU day 0, 1, 3 and 7 (7 days)
|
TNF alpha levels (serum inflammatory biomarker)
Time Frame: ICU day 0, 1, 3 and 7 (7 days)
|
TNF alpha, in pg/mL, from multiplex cytokine arrays
|
ICU day 0, 1, 3 and 7 (7 days)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jim Lewis, MD, Lawson Health Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Respiratory Distress Syndrome
- Respiratory System Agents
- Pulmonary Surfactants
Other Study ID Numbers
- 9890
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Bovine Lipid Extract Surfactant
-
The Hospital for Sick ChildrenUnknownMeconium Aspiration SyndromeCanada
-
Lady Hardinge Medical CollegeRecruitingMeconium Aspiration Syndrome | Surfactant DysfunctionIndia
-
Lady Hardinge Medical CollegeCompletedMeconium Aspiration SyndromeIndia
-
University of ManitobaHealth Sciences Centre, Winnipeg, Manitoba; University of Utah; St. Boniface... and other collaboratorsUnknownBronchopulmonary Dysplasia | Respiratory Distress Syndrome in Premature InfantCanada
-
Graminex LLCKGK Science Inc.CompletedUrinary IncontinenceCanada
-
Ramesh K AgarwalAll India Institute of Medical Sciences, New Delhi; Wellcome Trust; Lady Hardinge... and other collaboratorsUnknownRespiratory Distress Syndrome
-
Zhejiang UniversitySir Run Run Shaw HospitalUnknown
-
University of ThessalyGreek Ministry of Development; General Hospital of Trikala, Dept of Internal... and other collaboratorsCompletedHypercholesterolemiaGreece
-
SanofiCompleted
-
Oriflame Cosmetics ABCompletedHealthy | Skin ManifestationsSweden